JP2019511236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511236A5 JP2019511236A5 JP2018554069A JP2018554069A JP2019511236A5 JP 2019511236 A5 JP2019511236 A5 JP 2019511236A5 JP 2018554069 A JP2018554069 A JP 2018554069A JP 2018554069 A JP2018554069 A JP 2018554069A JP 2019511236 A5 JP2019511236 A5 JP 2019511236A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- car
- nucleic acid
- site
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323623P | 2016-04-15 | 2016-04-15 | |
| US62/323,623 | 2016-04-15 | ||
| US201662323675P | 2016-04-16 | 2016-04-16 | |
| US62/323,675 | 2016-04-16 | ||
| US201762461677P | 2017-02-21 | 2017-02-21 | |
| US62/461,677 | 2017-02-21 | ||
| US201762462243P | 2017-02-22 | 2017-02-22 | |
| US62/462,243 | 2017-02-22 | ||
| PCT/US2017/027601 WO2017180989A2 (en) | 2016-04-15 | 2017-04-14 | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511236A JP2019511236A (ja) | 2019-04-25 |
| JP2019511236A5 true JP2019511236A5 (https=) | 2020-05-28 |
| JP7058223B2 JP7058223B2 (ja) | 2022-04-21 |
Family
ID=59285314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554069A Active JP7058223B2 (ja) | 2016-04-15 | 2017-04-14 | トランスジェニックｔ細胞及びキメラ抗原受容体ｔ細胞組成物及び関連方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11377637B2 (https=) |
| EP (3) | EP4628587A3 (https=) |
| JP (1) | JP7058223B2 (https=) |
| KR (2) | KR102614675B1 (https=) |
| CN (1) | CN109790517B (https=) |
| AU (1) | AU2017250769B2 (https=) |
| BR (1) | BR112018071199A2 (https=) |
| ES (2) | ES2933961T3 (https=) |
| PT (2) | PT3443075T (https=) |
| SG (1) | SG11201808831TA (https=) |
| WO (1) | WO2017180989A2 (https=) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016211671B2 (en) | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| US11643668B2 (en) | 2015-06-17 | 2023-05-09 | The Uab Research Foundation | CRISPR/Cas9 complex for genomic editing |
| CA2989858A1 (en) * | 2015-06-17 | 2016-12-22 | The Uab Research Foundation | Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
| EP3359660B1 (en) | 2015-10-05 | 2019-12-04 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| CN117070468A (zh) * | 2015-10-05 | 2023-11-17 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| JP6928604B2 (ja) * | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CN109415687A (zh) * | 2016-04-07 | 2019-03-01 | 蓝鸟生物公司 | 嵌合抗原受体t细胞组合物 |
| US11377637B2 (en) | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| US10576167B2 (en) * | 2016-08-17 | 2020-03-03 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| KR102709329B1 (ko) * | 2016-10-19 | 2024-09-23 | 셀렉티스 에스.에이. | 개선된 면역 세포들 치료를 위한 타겟인 유전자 삽입 |
| CA3041831A1 (en) * | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of making genetically modified cells |
| US12303561B2 (en) | 2017-04-03 | 2025-05-20 | Biontech Us Inc. | Protein antigens and uses thereof |
| US11220538B2 (en) | 2017-05-01 | 2022-01-11 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| CA3067382A1 (en) | 2017-06-15 | 2018-12-20 | The Regents Of The University Of California | Targeted non-viral dna insertions |
| CA3068465A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| EP3658578A1 (en) * | 2017-07-26 | 2020-06-03 | Cellectis | Methods of antigen-dependent chimeric antigen receptor (car) immune cell selection |
| MX2020004185A (es) * | 2017-09-27 | 2021-01-08 | Univ Southern California | Nuevas plataformas para coestimulacion, nuevos diseños car y otras mejoras para terapia celular adoptiva. |
| KR102503130B1 (ko) * | 2017-10-27 | 2023-02-24 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 내인성 t 세포 수용체의 표적화된 대체 |
| US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| CA3090791A1 (en) * | 2018-02-11 | 2019-08-15 | Memorial Sloan-Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| CN112534044A (zh) * | 2018-02-16 | 2021-03-19 | 凯德药业股份有限公司 | 经修饰的多能干细胞及制备和使用方法 |
| US20200224160A1 (en) * | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
| EP3781176A4 (en) * | 2018-04-09 | 2022-05-25 | The Trustees of the University of Pennsylvania | METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR |
| CA3095795A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
| WO2019204397A1 (en) * | 2018-04-17 | 2019-10-24 | Wake Forest University Health Sciences | Methods and compositions for th9 cell mediated cancer treatment |
| WO2019226998A1 (en) * | 2018-05-25 | 2019-11-28 | The Regents Of The University Of California | Genetic engineering of endogenous proteins |
| JP2021525530A (ja) * | 2018-06-01 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
| BR112020025764A2 (pt) | 2018-06-19 | 2021-05-11 | Biontech Us Inc. | neoantígenos e usos dos mesmos |
| CN110616188B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种通用型car-t细胞及其制备方法和应用 |
| US12359169B2 (en) | 2018-06-20 | 2025-07-15 | Shanghai Longyao Biotechnology Inc., Ltd. | Universal CAR-T cell and preparation method and use thereof |
| CA3104862A1 (en) * | 2018-07-03 | 2020-01-09 | Sotio, LLC | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| CN112752838A (zh) * | 2018-07-26 | 2021-05-04 | 国立大学法人京都大学 | 制备引入外源抗原受体的细胞的方法 |
| KR20210045418A (ko) | 2018-08-14 | 2021-04-26 | 소티오, 엘엘씨 | 크렙스 사이클을 조정하는 트랜스 대사 분자와 조합된 키메라 항원 수용체 폴리펩타이드 및 이의 치료적 용도 |
| SG11202104524YA (en) | 2018-11-01 | 2021-05-28 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for t cell engineering |
| EP3883585A4 (en) * | 2018-11-20 | 2022-12-14 | Innovative Cellular Therapeutics Holdings, Ltd. | MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF |
| KR102840400B1 (ko) | 2018-12-12 | 2025-08-04 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| ES2944062T3 (es) * | 2018-12-19 | 2023-06-19 | Inst Nat Sante Rech Med | Células T invariantes asociadas a la mucosa (MAIT) que expresan receptores de antígenos quiméricos |
| KR20210125509A (ko) * | 2019-02-01 | 2021-10-18 | 케이에스큐 세러퓨틱스 인코포레이티드 | 개선된 면역요법을 위한 유전자-조절 조성물 및 방법 |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| CA3130489A1 (en) * | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| CN113924103B (zh) * | 2019-03-06 | 2025-02-14 | 莱蒂恩技术公司 | 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法 |
| CN113661173B (zh) | 2019-03-29 | 2024-10-01 | 豪夫迈·罗氏有限公司 | 通过以限定的组织形式靶向整合多个表达盒来产生表达FcRn的细胞的方法 |
| AU2020271523A1 (en) * | 2019-04-11 | 2021-10-14 | Fate Therapeutics, Inc. | CD3 reconstitution in engineered iPSC and immune effector cells |
| EP3962519A1 (en) | 2019-05-01 | 2022-03-09 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| US20220218752A1 (en) * | 2019-05-16 | 2022-07-14 | University Of Washington | Lockr-mediated recruitment of car t cells |
| WO2020254352A1 (en) * | 2019-06-19 | 2020-12-24 | F. Hoffmann-La Roche Ag | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| CA3148072A1 (en) | 2019-07-19 | 2021-01-28 | Memorial Sloan-Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| US20220251572A1 (en) | 2019-07-23 | 2022-08-11 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| CN117925528A (zh) * | 2019-07-24 | 2024-04-26 | 浙江煦顼技术有限公司 | 具有增强记忆t细胞表型的修饰t细胞 |
| AU2020355025A1 (en) * | 2019-09-23 | 2022-04-07 | Regents Of The University Of Minnesota | Genetically-edited immune cells and methods of therapy |
| JP2022550534A (ja) * | 2019-09-25 | 2022-12-02 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 無色素毛様体上皮細胞に特異的なプロモーター |
| SG10201909544YA (en) * | 2019-10-11 | 2021-05-28 | Nat Univ Singapore | Genetically Modified T Cells And Uses Thereof |
| BR112022009137A2 (pt) * | 2019-11-13 | 2022-07-26 | Crispr Therapeutics Ag | Métodos de fabricação de células t com receptor de antígeno quimérico (car) |
| TW202132333A (zh) * | 2019-11-13 | 2021-09-01 | 瑞士商Ｃｒｉｓｐｒ治療公司 | 製造可表達嵌合抗原受體的ｔ細胞製法 |
| CN113122576A (zh) * | 2019-12-31 | 2021-07-16 | 博雅辑因（北京）生物科技有限公司 | 一种通用型truck-t细胞、其制备方法以及用途 |
| WO2021137241A1 (en) * | 2020-01-02 | 2021-07-08 | Edity Therapeutics Ltd. | Delivery compositions and methods |
| WO2021173925A1 (en) * | 2020-02-28 | 2021-09-02 | Wisconsin Alumni Research Foundation | Nonviral generation of genome edited chimeric antigen receptor t cells |
| CA3172423A1 (en) * | 2020-03-20 | 2021-03-22 | Alex WESSELHOEFT | Circular rna compositions and methods |
| GB202006903D0 (en) * | 2020-05-11 | 2020-06-24 | Adaptimmune Ltd | Modified iPSCs |
| JP2023532347A (ja) * | 2020-06-29 | 2023-07-27 | セル メディカ，インコーポレイテッド | キメラ抗原受容体の緊張性シグナル伝達を減少させる方法および組成物 |
| WO2022011065A1 (en) * | 2020-07-07 | 2022-01-13 | The Nemours Foundation | Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer |
| CA3190266A1 (en) | 2020-07-30 | 2022-02-03 | Institut Curie | Immune cells defective for socs1 |
| EP4192941A1 (en) * | 2020-08-07 | 2023-06-14 | Neogene Therapeutics B.V. | Methods to enrich genetically engineered t cells |
| WO2022072712A1 (en) * | 2020-09-30 | 2022-04-07 | Vor Biopharma Inc. | Chimeric antigen receptor expression systems |
| AU2021392094A1 (en) * | 2020-12-01 | 2023-07-06 | Lepton Pharmaceuticals Ltd. | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4019538A1 (en) | 2020-12-22 | 2022-06-29 | Charité - Universitätsmedizin Berlin | Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes |
| EP4304632A2 (en) | 2021-03-11 | 2024-01-17 | Mnemo Therapeutics | Tumor neoantigenic peptides |
| US20250041412A1 (en) | 2021-03-11 | 2025-02-06 | Institut Curie | Transmembrane neoantigenic peptides |
| WO2022189639A1 (en) | 2021-03-11 | 2022-09-15 | Mnemo Therapeutics | Tumor neoantigenic peptides and uses thereof |
| AU2022272317A1 (en) * | 2021-05-14 | 2023-11-30 | Appia Bio, Inc. | Production of engineered t cells from stem cells |
| WO2023057285A1 (en) | 2021-10-06 | 2023-04-13 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
| US20230124097A1 (en) * | 2021-10-14 | 2023-04-20 | Appia Bio, Inc. | Engineering stem cell t cells with multiple t cell receptors |
| AU2022366987A1 (en) | 2021-10-14 | 2024-05-16 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| WO2023091783A1 (en) * | 2021-11-22 | 2023-05-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Engineered immune cells with reduced sirt6 expression |
| EP4456910A1 (en) | 2021-12-28 | 2024-11-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
| US20250115916A1 (en) | 2022-01-21 | 2025-04-10 | Mnemo Therapeutics | Modulation of suv39h1 expression by rnas |
| CN115304679B (zh) * | 2022-01-21 | 2024-07-16 | 郑州大学第一附属医院 | 一种促进t细胞分化的限制型car及其应用 |
| WO2023178227A2 (en) * | 2022-03-17 | 2023-09-21 | University Of Florida Research Foundation, Incorporated | Chimeric lactate receptor engineered t cells |
| WO2023225670A2 (en) * | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2024039576A2 (en) | 2022-08-19 | 2024-02-22 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| EP4580604A2 (en) * | 2022-09-02 | 2025-07-09 | OncoSenX, Inc. | Compositions and methods for in vivo expression of chimeric antigen receptors |
| BE1031219B1 (fr) | 2022-12-28 | 2024-07-29 | Quidditas Sa | Composition, cellules immunitaires la comprenant et utilisation de ces dernières |
| WO2025096560A1 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| AU2024369584A1 (en) * | 2023-10-30 | 2026-04-09 | Allogene Therapeutics, Inc. | Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof |
| WO2025163107A1 (en) | 2024-02-01 | 2025-08-07 | Institut Gustave Roussy | Immune cells defective for znf217 and uses thereof |
| WO2025213167A1 (en) * | 2024-04-05 | 2025-10-09 | Roswell Park Cancer Institute Corporation | Complement signaling as a t-cell checkpoint in the tumor microenvironment (tme) |
| WO2025259702A1 (en) * | 2024-06-10 | 2025-12-18 | Adoptracell, Inc. | Method for generating car-t cells in which car expression is coupled with expression of endogenous foxp3, and compositions and methods of use thereof |
| WO2026062222A1 (en) | 2024-09-20 | 2026-03-26 | Institut Curie | Novel protein isoforms and uses |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| EP1409646B1 (en) | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
| IL162111A0 (en) | 2001-12-22 | 2005-11-20 | 4Antibody Ag | Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo |
| DK1321477T3 (da) | 2001-12-22 | 2005-02-14 | 4Antibody Ag | Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2005026718A1 (en) | 2003-08-28 | 2005-03-24 | Five Prime Therapeutics, Inc. | Stem cell libraries |
| US20110213288A1 (en) | 2007-04-23 | 2011-09-01 | The Board Of Regents, The University Of Texas System | Device And Method For Transfecting Cells For Therapeutic Uses |
| US9051391B2 (en) | 2007-06-11 | 2015-06-09 | Takara Bio Inc. | Method for expression of specific gene |
| EP3156494B8 (en) | 2008-12-04 | 2018-09-19 | Sangamo Therapeutics, Inc. | Genome editing in rats using zinc-finger nucleases |
| WO2011011767A1 (en) * | 2009-07-24 | 2011-01-27 | Sigma-Aldrich Co. | Method for genome editing |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| CA2993567C (en) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| MY169358A (en) | 2011-08-23 | 2019-03-26 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| WO2013158309A2 (en) | 2012-04-18 | 2013-10-24 | The Board Of Trustees Of The Leland Stanford Junior University | Non-disruptive gene targeting |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| EP2906684B8 (en) * | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP4303232A3 (en) | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| US9499855B2 (en) | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| JP6346266B2 (ja) | 2013-03-21 | 2018-06-20 | サンガモ セラピューティクス， インコーポレイテッド | 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊 |
| AU2014248119B2 (en) | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| CA2909701C (en) | 2013-04-17 | 2022-12-06 | Baylor College Of Medicine | Immunosuppressive tgf-.beta. signal converter |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| EP3119897A1 (en) | 2014-03-21 | 2017-01-25 | Cellectis | Engineering mammalian genome using dna-guided argonaute interference systems (dais) |
| EP3134515B1 (en) | 2014-04-24 | 2019-03-27 | Board of Regents, The University of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| US10053708B2 (en) | 2014-05-09 | 2018-08-21 | Research Foundation Of The City University Of New York | TCR(alpha)-LCR-derived gene regulatory cassettes |
| EP3152319A4 (en) * | 2014-06-05 | 2017-12-27 | Sangamo BioSciences, Inc. | Methods and compositions for nuclease design |
| RS60359B1 (sr) | 2014-06-06 | 2020-07-31 | Regeneron Pharma | Postupci i kompozicije za modifikovanje ciljanog lokusa |
| CA2959428A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| US11319555B2 (en) * | 2014-11-20 | 2022-05-03 | Duke University | Compositions, systems and methods for cell therapy |
| KR20260048600A (ko) | 2015-03-27 | 2026-04-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 변형된 t 세포 및 이의 제조 및 사용 방법 |
| WO2016166268A1 (en) | 2015-04-17 | 2016-10-20 | Cellectis | Engineering animal or plant genome using dna-guided argonaute interference systems (dais) from mesophilic prokaryotes |
| CN207773375U (zh) * | 2015-05-15 | 2018-08-28 | 奥罗皮艇有限公司 | 可折叠船只 |
| EP3322297B1 (en) * | 2015-07-13 | 2024-12-04 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| CN117070468A (zh) | 2015-10-05 | 2023-11-17 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| EP3359660B1 (en) * | 2015-10-05 | 2019-12-04 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| CA3003152A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| JP6928604B2 (ja) | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| EP3377523A4 (en) | 2015-11-19 | 2019-06-19 | The Regents of The University of California | CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF |
| MX2018010924A (es) | 2016-03-11 | 2019-02-13 | Bluebird Bio Inc | Células efectoras inmunitarias con edición genómica. |
| IL261713B2 (en) | 2016-03-19 | 2023-09-01 | F1 Oncology Inc | Methods and preparations for the transfer of lymphocytes and their regulated expansion |
| CN109415687A (zh) | 2016-04-07 | 2019-03-01 | 蓝鸟生物公司 | 嵌合抗原受体t细胞组合物 |
| US11377637B2 (en) | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
-
2017
- 2017-04-14 US US16/091,494 patent/US11377637B2/en active Active
- 2017-04-14 KR KR1020227029151A patent/KR102614675B1/ko active Active
- 2017-04-14 EP EP25181439.8A patent/EP4628587A3/en active Pending
- 2017-04-14 CN CN201780037351.1A patent/CN109790517B/zh active Active
- 2017-04-14 AU AU2017250769A patent/AU2017250769B2/en active Active
- 2017-04-14 WO PCT/US2017/027601 patent/WO2017180989A2/en not_active Ceased
- 2017-04-14 EP EP22197444.7A patent/EP4180519B1/en active Active
- 2017-04-14 SG SG11201808831TA patent/SG11201808831TA/en unknown
- 2017-04-14 EP EP17735670.6A patent/EP3443075B1/en active Active
- 2017-04-14 KR KR1020187032919A patent/KR102437015B1/ko active Active
- 2017-04-14 ES ES17735670T patent/ES2933961T3/es active Active
- 2017-04-14 PT PT177356706T patent/PT3443075T/pt unknown
- 2017-04-14 PT PT221974447T patent/PT4180519T/pt unknown
- 2017-04-14 JP JP2018554069A patent/JP7058223B2/ja active Active
- 2017-04-14 BR BR112018071199-3A patent/BR112018071199A2/pt active Search and Examination
- 2017-04-14 ES ES22197444T patent/ES3039670T3/es active Active
-
2022
- 2022-05-25 US US17/824,650 patent/US12404316B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511236A5 (https=) | ||
| KR102691932B1 (ko) | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 | |
| AU2018207281B2 (en) | Modulating expression of polypeptides via new gene switch expression systems | |
| KR102495308B1 (ko) | 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터 | |
| US20220089671A1 (en) | Transposon-based transfection system for primary cells | |
| JP7005346B2 (ja) | 養子細胞免疫療法の有効性を増強させるための組成物および方法 | |
| JP6161098B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| IL274179B1 (en) | Targeted replacement of endogenous T cell receptors | |
| Gowrishankar et al. | Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells | |
| ES3041600T3 (en) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogennous foxp3 gene | |
| JP2021530999A5 (https=) | ||
| KR20200015939A (ko) | 신규의 세포 태그의 발현 | |
| JP2021518161A5 (https=) | ||
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| CN109415687A (zh) | 嵌合抗原受体t细胞组合物 | |
| KR20170108946A (ko) | Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도 | |
| Campillo-Davo et al. | Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific T cell receptors with minimal TCR mispairing | |
| CN106535925A (zh) | 基于car的免疫治疗 | |
| JP2021518747A (ja) | Ｒｎａ不安定化エレメントを使用した遺伝子発現の調整 | |
| US20150275209A1 (en) | Compositions and methods for enhancing cancer immunotherapy | |
| JP6723164B2 (ja) | Ｔ細胞集団の改変方法 | |
| Middelburg et al. | The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent | |
| US20230279352A1 (en) | Methods for generating primary immune cells | |
| US11098283B2 (en) | T cells modified to overexpress c-Myb | |
| WO2010114129A1 (ja) | Ｔ細胞レセプター及び該レセプターをコードする核酸 |